Announced details
Achondroplasia (Achondroplasia, ACH)
Continued growth-promoting effects were confirmed in 4 responders. The AGV of responders exceeded Voxzogo's average height growth velocity (+1.5–1.7 cm/year).
11 patients who transitioned to the long-term treatment study (Cohort 1: 5 patients; Cohort 2: 6 patients). 7 patients are still participating in the clinical trial. 9 patients received continuous treatment for more than 1 year.
No impact on results for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol (treatment for achondroplasia) |
| Applicable area | Achondroplasia (Achondroplasia, ACH) |
| Quantitative Effects | Continued growth-promoting effects were confirmed in 4 responders. The AGV of responders exceeded Voxzogo's average height growth velocity (+1.5–1.7 cm/year). |
| Usage history | 11 patients who transitioned to the long-term treatment study (Cohort 1: 5 patients; Cohort 2: 6 patients). 7 patients are still participating in the clinical trial. 9 patients received continuous treatment for more than 1 year. |
| Impact on Business Performance | No impact on results for the fiscal year ending March 2027 |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because interim data from the long-term treatment study became available and continued efficacy in responders was confirmed.